An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Expanded Access and Open Label Extension Study of SER-109 to Prevent Recurrent Clostridium Difficile Infection

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease